ImmunoPrecise Antibodies Files 6-K with Press Release
Ticker: HYFT · Form: 6-K · Filed: Jan 27, 2025 · CIK: 1715925
Sentiment: neutral
Topics: filing, press-release, foreign-private-issuer
TL;DR
IPA filed a 6-K on Jan 27, 2025, with a press release attached. Check it for updates.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on January 27, 2025, reporting a press release dated January 27, 2025. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The principal executive office is located in Austin, Texas.
Why It Matters
This filing serves as an update for investors, providing information about the company's reporting status and including a press release that may contain material business developments.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, with no immediate indication of significant financial or operational changes.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- January 27, 2025 (date) — Date of the press release and filing
- Jennifer Bath (person) — Signatory for the company
- Austin, Texas (location) — Location of principal executive office
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release dated January 27, 2025, is included with this filing.
What is ImmunoPrecise Antibodies Ltd.'s fiscal year end?
ImmunoPrecise Antibodies Ltd.'s fiscal year ends on April 30th.
Which form will ImmunoPrecise Antibodies Ltd. use for its annual reports?
ImmunoPrecise Antibodies Ltd. will file its annual reports under Form 20-F.
Who signed this Form 6-K on behalf of ImmunoPrecise Antibodies Ltd.?
Jennifer Bath signed the Form 6-K on behalf of ImmunoPrecise Antibodies Ltd.
Filing Stats: 144 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-01-27 10:00:03
Filing Documents
- press_release_jan_27_202.htm (6-K) — 23KB
- ipa-ex99_1.htm (EX-99.1) — 16KB
- 0000950170-25-009017.txt ( ) — 40KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: January 27, 2025 By: /s/ Jennifer Bath Name: Jennifer Bath Title: President and Chief Executive Officer